Engineering strategies to overcome the current roadblocks in CAR T cell therapy

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven — and impressive — therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. Nevertheless, various barrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiq, Sarwish, Hackett, Christopher S., Brentjens, Renier J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223338/
https://www.ncbi.nlm.nih.gov/pubmed/31848460
http://dx.doi.org/10.1038/s41571-019-0297-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223338/
https://www.ncbi.nlm.nih.gov/pubmed/31848460
http://dx.doi.org/10.1038/s41571-019-0297-y

Ejemplares similares